Published on 22/12/2025
How to Choose the Right Devices for Your Clinical Protocol
Why Device Selection Matters in Modern Trials
Wearable technologies are transforming how clinical trials are conducted, offering real-time data capture, continuous monitoring, and improved patient convenience. However, selecting the appropriate device is critical. A poorly chosen device can compromise data quality, affect patient adherence, and even jeopardize regulatory compliance. Clinical teams must align device capabilities with protocol endpoints, site capacity, and subject demographics.
Whether deploying ECG patches, smartwatches, glucose sensors, or activity trackers, device selection must be intentional—not opportunistic. Incorporating a structured assessment framework is essential for GxP-compliant trials, especially for pivotal studies.
Regulatory Considerations for Device Selection
Before selecting a wearable or sensor device, it’s crucial to evaluate its regulatory status. Key checkpoints include:
- ✅ FDA 510(k) or De Novo clearance (for US trials)
- ✅ CE marking under the Medical Device Regulation (EU MDR)
- ✅ Device classification and associated risk category
- ✅ Validation status for the intended use (e.g., heart rate monitoring vs. arrhythmia detection)
The FDA guidance on digital health technologies provides comprehensive criteria on acceptability of wearables in regulated trials. Sponsors must ensure that device usage complies with protocol-specific endpoint definitions, especially for primary or secondary
Key Technical Parameters to Evaluate
Device capabilities must align with protocol expectations. Important technical criteria include:
- ✅ Signal fidelity: Resolution and frequency of data collection (e.g., 1Hz for heart rate, 100Hz for ECG)
- ✅ Battery life: Must cover the intended recording period (e.g., 72 hours, 14 days)
- ✅ Data storage: Local buffering vs. real-time transmission
- ✅ Connectivity: Bluetooth, cellular, Wi-Fi compatibility with patient smartphones
- ✅ APIs for integration: Compatibility with EDC, CTMS, or eSource platforms
For example, in a sleep quality study, a device with actigraphy and validated sleep stage detection algorithm may be preferred over generic fitness trackers. Sponsors can refer to device performance reports or validation publications to cross-check claims.
Patient Usability and Compliance
Even the most sophisticated device will fail if participants struggle to use it. Usability impacts both data integrity and dropout rates. The following factors should be considered:
- ✅ Wear comfort (e.g., wristbands vs. chest patches)
- ✅ Visual instructions and language support
- ✅ Charging simplicity and reminders
- ✅ Durability for target populations (e.g., elderly, pediatric)
Conducting a pilot usability study is recommended before full-scale deployment. Wearable training SOPs should be integrated into your Investigator Site File (ISF). Refer to this GMP case study on device usability to understand best practices for reducing non-compliance due to user error.
Case Study: Protocol-Device Mismatch
In a 2022 oncology trial using hydration tracking sensors, sponsors selected a wrist device that only measured skin impedance. However, the protocol required accurate electrolyte estimation for dose titration. This mismatch resulted in a major protocol deviation. After regulatory intervention, the device was replaced mid-study, increasing budget by 18% and extending timelines by 3 months.
This example underscores why device selection must be led by protocol requirements, not vendor availability or novelty.
Data Privacy, Security, and Interoperability
Clinical trials generate sensitive health data. Devices must meet global data protection requirements including GDPR and HIPAA. Sponsors must also consider:
- ✅ Data encryption at rest and in transit
- ✅ Role-based access to raw data
- ✅ Cloud storage location and certifications (e.g., ISO 27001)
- ✅ De-identification and pseudonymization of trial data
Furthermore, interoperability remains a bottleneck. Devices should support standard data formats like FHIR or CDISC ODM. Without interoperability, integrating device data into electronic data capture (EDC) systems becomes resource-intensive and error-prone. Sponsors must involve IT and data management teams early in the vendor selection process.
GxP Validation and Vendor Qualification
All devices used in regulated trials must be validated per GxP expectations. This includes:
- ✅ Installation Qualification (IQ)
- ✅ Operational Qualification (OQ)
- ✅ Performance Qualification (PQ)
Vendor qualification must also be documented. Sponsors should request:
- ✅ Validation documentation
- ✅ Change control history
- ✅ Support SLAs and backup plans
- ✅ Prior audit outcomes, if available
Auditing vendors who supply devices for clinical use is becoming a standard expectation by both FDA and EMA inspectors. Refer to GxP Blockchain Templates for sample qualification checklists and SOPs.
Trial Logistics and Device Supply Chain
Devices must be available in required quantities across all sites. Logistics planning includes:
- ✅ Multi-region import/export licenses
- ✅ Customs clearance timelines
- ✅ Battery shipping restrictions
- ✅ Device calibration checks before first use
- ✅ Repair or replacement policies for damaged units
For decentralized or hybrid trials, the devices may be shipped directly to participants. This requires integration with home health providers or courier services and increases the importance of remote tech support.
Aligning Device Features with Protocol Endpoints
The device must support validated endpoints. For instance, a trial measuring step count for sarcopenia progression must ensure the device algorithm is validated against industry standards like those published by WHO or ICH.
Endpoints involving sleep stages, glucose trends, or atrial fibrillation detection need to match with the device’s specifications and peer-reviewed performance benchmarks. Sponsors should request:
- ✅ White papers on device accuracy
- ✅ Algorithm validation datasets
- ✅ Comparative studies with gold-standard references
Conclusion
Device selection for clinical trials is not merely a technology choice—it is a clinical, regulatory, operational, and patient-centric decision. Protocol success hinges on ensuring the device is technically capable, regulatory compliant, user-friendly, and logistically feasible.
By building a device selection checklist, qualifying vendors thoroughly, and aligning device features with endpoints and subject needs, sponsors can mitigate risks and improve trial outcomes. Always involve cross-functional input early in the selection process—from clinical science to regulatory affairs to data management.